Home

Transistor Magia disprezzare camillo porta maugeri futuro Perdere Cordiali saluti

April 2020 Reviewer of the Month - Reviewer Name: European Urology
April 2020 Reviewer of the Month - Reviewer Name: European Urology

Immune-based combination therapy for metastatic kidney cancer | Nature  Reviews Nephrology
Immune-based combination therapy for metastatic kidney cancer | Nature Reviews Nephrology

Ecco il bracciale che aiuta i malati di tumore Parte da Pavia lo studio  premiato in Europa - La Provincia Pavese
Ecco il bracciale che aiuta i malati di tumore Parte da Pavia lo studio premiato in Europa - La Provincia Pavese

Single nucleotide polymorphisms in angiogenesis-related genes and outcomes  from antiangiogenic therapies in renal cell carcinoma: really a step  towards personalized oncology, or not at all? - Porta - Annals of  Translational Medicine
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all? - Porta - Annals of Translational Medicine

Numero 3, Luglio-Settembre - Azienda ospedaliera S.Camillo ...
Numero 3, Luglio-Settembre - Azienda ospedaliera S.Camillo ...

Press & Media - Capable
Press & Media - Capable

Terapie di combinazione: il punto su melanoma, carcinoma polmonare e  carcinoma renale - OncoInfo
Terapie di combinazione: il punto su melanoma, carcinoma polmonare e carcinoma renale - OncoInfo

Nicole Gri (@NikGri93) / Twitter
Nicole Gri (@NikGri93) / Twitter

The role of endothelial colony forming cells in kidney cancer's  pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A  speculative review - ScienceDirect
The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review - ScienceDirect

Axitinib Did Not Meet Study End Point in mRCC, but Dosing Found Feasible -  Cancer Therapy Advisor
Axitinib Did Not Meet Study End Point in mRCC, but Dosing Found Feasible - Cancer Therapy Advisor

maugeri - insalutenews.it
maugeri - insalutenews.it

JPM | Free Full-Text | Validation of a Novel Three-Dimensional (3D Fusion)  Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome  Intratumoral Heterogeneity: The Meet-Uro 18 Study
JPM | Free Full-Text | Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study

An evaluation of UGN-101, a sustained-release hydrogel polymer-based  formulation containing mitomycin-C, for the treatment of upper urothelial  carcinomas: Expert Opinion on Pharmacotherapy: Vol 21, No 18
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas: Expert Opinion on Pharmacotherapy: Vol 21, No 18

Carcinoma renale avanzato: una terapia innovativa in prima linea - OncoInfo
Carcinoma renale avanzato: una terapia innovativa in prima linea - OncoInfo

Treatment sequencing strategies in metastatic renal cell carcinoma: A  critical interpretation of available data - Mimma Rizzo, Matteo Santoni, Camillo  Porta, 2020
Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data - Mimma Rizzo, Matteo Santoni, Camillo Porta, 2020

Pavia, l'oncologia della Maugeri al top - Cronaca - ilgiorno.it
Pavia, l'oncologia della Maugeri al top - Cronaca - ilgiorno.it

Camillio PORTA | Università degli Studi di Bari Aldo Moro, Bari |  Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana  (DIMO) | Research profile
Camillio PORTA | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO) | Research profile

WHICH IMMUNOTHERAPY IS THE STANDARD 1ST LINE THERAPY IN mRCC – IMMUNE  COMBOS WITH A TKI
WHICH IMMUNOTHERAPY IS THE STANDARD 1ST LINE THERAPY IN mRCC – IMMUNE COMBOS WITH A TKI

Kidney Cancer: What Is New in the Second-Line Treatment Setting?
Kidney Cancer: What Is New in the Second-Line Treatment Setting?

Mirrors of Medicine - PinPoint cases - Experten und Mitarbeiter
Mirrors of Medicine - PinPoint cases - Experten und Mitarbeiter

Untitled
Untitled

Mirrors of Medicine - PinPoint cases - Esperti e collaboratori
Mirrors of Medicine - PinPoint cases - Esperti e collaboratori

PDF) Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma  family protein pRb2/p130 interaction in human mesothelioma
PDF) Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction in human mesothelioma

SV40 Replication in Human Mesothelial Cells Induces HGF/Met Receptor  Activation: A Model for Viral-Related Carcinogenesis of Hum
SV40 Replication in Human Mesothelial Cells Induces HGF/Met Receptor Activation: A Model for Viral-Related Carcinogenesis of Hum

2018 Impact Factor 17.298
2018 Impact Factor 17.298

COVID-19: il ruolo degli oncologi - OncoInfo
COVID-19: il ruolo degli oncologi - OncoInfo

Frontiers | Artificial intelligence-based prediction of overall survival in  metastatic renal cell carcinoma
Frontiers | Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma

Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk  Factors in CheckMate 214 - European Urology
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214 - European Urology